Eli Lilly (LLY) emerges among the top performers in Big Pharma in 2024 with obesity drug success, while Novo Nordisk (NVO) ...

INR:1659. sivasspor vs kasımpaşa lineups Novo Nordisk's Ozempic has been submitted to EMA Following Roche and Takeda, Sosei wins another $480 m ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...

From politics to pop culture, climate to conflict, 2024 was a year of tumbling records … but not always for the best reasons.

Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.

Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.

"Ozempic Santa" Elon Musk revealed he's been using a type 2 diabetes medication to lose weight: "Technically, Mounjaro, but that doesn’t have the same ring to it." ...

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...